Emerging World Pharma Inc. Strategic Partner African Global Pharma GH in Negotiations to Finalize Agreement for Sale and Dist...
15 11월 2012 - 10:30PM
Marketwired
Emerging World Pharma Inc. (PINKSHEETS: EWPI) -- Emerging World
Pharma Inc. strategic partner African Global Pharma Corp. (AGP) is
negotiating an agreement to distribute our full line of
pharmaceutical products to several West African countries. Ghana
acts as the gateway to a huge sub-regional market of over 250
million people. This is the first endeavour for AGP to broaden our
market base outside of Ghana. The current line of medicines being
produced in AGP's Ghana manufacturing facility are Glaten®
(anti-hypertensive), Glibenclamide (anti-diabetic), Globartem®,
Gloderp (anti-malarials) and Paracetamol (pain relieving
analgesic). "We are proud to announce this collaboration. Together
with African Global Pharma GH, our company will continue to expand
the distribution of our product line in the West African market. We
see great commercial potential in the product line going forward.
We endeavor to ensure the availability of world class, quality
medicines within reach at affordable prices," stated Emerging World
Pharma President Steve Ignatavicius.
About African Global Pharma, Ghana
African Global Pharma (Ghana) Limited is an affiliated company
of African GlobalPharma Corp. of Canada with business partnership
with the Catholic Diocese of Sunyani to distribute all our
manufactured drugs to the Catholic Mission Hospitals. African
Global Pharma's production facility in Sunyani, Ghana was fully
rehabilitated and built by African Global Pharma Corp., Canada. The
plant and its operations are headquartered in Sunyani at the
Diocesan Bldg.
For more on AGP click here
http://www.globalpharmacorp.ca/african-gp-ghana.html
About Emerging World Pharma Inc.
Emerging World Pharma Inc. is an investor in generic based
pharmaceutical companies manufacturing within developing nations.
The company focuses its investments on generic pharmaceutical
companies that have contracts with three major buyer groups;
church, government and wholesalers. Market research shows that
these branches are the most secure, protected and reputable for the
distribution of medicines.
For more on Emerging World Pharma Inc. click here
http://www.emergingpharma.com/
Forward Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Statements in this release that are forward-looking
statements are based on current expectations and assumptions that
are subject to known and unknown risks, uncertainties, or other
factors which may cause actual results, performance, or
achievements of the company to be materially different from any
future results, performance, or achievements expressed or implied
by such forward-looking statements. Actual results could differ
materially because of factors such as the effect of general
economic and market conditions, entry into markets with vigorous
competition, market acceptance of new products and services,
continued acceptance of existing products and services,
technological shifts, and delays in product development and related
product release schedules, any of which may cause revenues and
income to fall short of anticipated levels. All information in this
release is as of the date of this release. The company undertakes
no duty to update any forward-looking statement to conform the
statement to actual results or changes in the company's
expectations.
Contact: Joel Everret Emerging World Pharma Inc. Investor
Relations Division 703-646-2633 Email: info@emergingpharma.com
Website: http://www.emergingpharma.com/
Emerging World Pharma (CE) (USOTC:EWPI)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Emerging World Pharma (CE) (USOTC:EWPI)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024